2020 Fiscal Year Final Research Report

Gelatin hydrogels with eicosapentaenoic acid can prevent osteoarthritis progression in vivo in a mouse model

Research Project

PDF

Project/Area Number	18K09105
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56020:Orthopedics-related
Research Institution	Kobe University
Principal Investigator	Hayashi Shinya 神戸大学, 医学部附属病院, 助教 (20437487)
Co-Investigator(Kenkyū-buntansha)	松本知之神戸大学, 医学部附属病院, 講師 (50546588) 橋本慎吾神戸大学, 医学研究科, 特命助教 (20457089) 高山孝治神戸大学, 医学部附属病院, 医学研究員 (80546490)
Project Period (FY)	2018-04-01 – 2021-03-31
Keywords	EPA / ゼラチンハイドロゲル
Outline of Final Research Achievements	This study aimed to investigate the effect of EPA-incorporating gelatin hydrogels on osteoarthritis (OA) progression in vivo.Ten-week-old male C57BL/6J mice were randomly divided into six groups (six mice each): sham,destabilization of the medial meniscus (DMM), Corn (DMM + corn oil ), EPA-I (DMM + corn oil + 3 mg/ml EPA), Control (DMM + control gelatin hydrogels), and EPA-G (DMM + 3 mg/ml EPA-incorporating gelatin hydrogels) groups. Mice were then euthanized 8 weeks after DMM or sham surgery, and subjected to histological evaluation. Histologic score was significantly improved in EPA-G compared to in EPA-I. MMP-3-, MMP-13-, IL-1β-, and p-IKK α/β-positive cell ratio was significantly improved in EPA-G compared to in EPA-I. However, CD86- and CD163-positive cell ratio was not significantly different between EPA-I and EPA-G. EPA-incorporating gelatin hydrogels can prevent OA progression in vivo more effectively than single injection of EPA.
Free Research Field	軟骨代謝学
Academic Significance and Societal Importance of the Research Achievements	変形性関節症に対する新規治療薬の開発で現在のところ効果的且つ安全性の高い治療法は無い。EPAは抗酸化剤としての機能だけでなく、近年抗炎症作用も有する報告もあり、多機能を有することが予想されEPAの他疾患への応用も含め機能を解明することが本研究の学術的意義であり、一方でEPAは循環器系やアルツハイマー病などの治療薬としてすでに使用されており、薬としての安全性は担保されているため変形性関節症の治療薬として即戦力になることが期待される点で社会的意義がある。